Key result
SUBCUT HF II evaluates subcutaneous furosemide versus IV therapy for early HF discharge.
Why the study?
Heart failure hospitalisations are frequent and lengthy, usually requiring intravenous diuretics, prompting evaluation of an alternative ambulatory care strategy using subcutaneous furosemide via a wearable pump.
Does early supported discharge using subcutaneous furosemide via a wearable pump improve days spent alive and out of hospital at 30 days in patients admitted with heart failure compared to continued in-patient intravenous furosemide?
Does early supported discharge using subcutaneous furosemide via a wearable pump improve days spent alive and out of hospital at 30 days in patients admitted with heart failure compared to continued in-patient intravenous furosemide?
The SUBCUT HF II trial will determine if early discharge with subcutaneous furosemide via a wearable pump is a safe and effective alternative to continued in-patient intravenous diuresis for heart failure.
Answers are grounded in this paper and cite their sources.
May enable safe early HF discharge if effective; delivers first RCT evidence on wearable subcutaneous furosemide.
Introduction Heart failure (HF) hospitalisations are frequent and lengthy, and usually involve treatment with intravenous diuretics to relieve congestion. SUBCUT HF II is evaluating the safety and efficacy of an alternative ambulatory care strategy using a novel subcutaneous formulation of furosemide delivered via a wearable pump. Methods The SUBCUT HF II trial is a multicentre, randomised, active comparator trial involving 20 hospitals in the UK. Eligible participants are patients with HF receiving in-patient treatment with intravenous loop diuretic therapy. Patients are randomised to either early supported discharge, using a novel formulation of subcutaneous furosemide (SQIN-furosemide) administered by a wearable pump (SQIN-infusor), or continued in-patient treatment using intravenous furosemide. The primary end point is days spent alive and out of hospital at 30 days. As of October 2025, 168 of 170 patients have been randomised. Conclusion The SUBCUT HF II trial is testing the safety and efficacy of an ambulatory care approach to managing patients presenting to hospital with HF. Trial Registration ClinicalTrials.gov identifier NCT05419115
No takes yet. Share an insight, caveat, or question.
Campbell et al. (2026) studied this question. The SUBCUT HF II trial is evaluating subcutaneous furosemide for early discharge in heart failure patients, aiming to improve days alive and out of hospital within 30 days.
Synapse has enriched 10 related papers. Consider them for comparative context: